Galecto

IPO

Redefining care for people with blood disorders

Galecto is a biotech company in Copenhagen, Denmark, founded in 2010. It has raised $446.9M across 4 rounds, most recently a $285.0M Series C in November 2025.

Employees
11–50
Founded
2010
Business Model
B2B
Total Funding
$446.9M
Last Round
$285.0M Series CNov 2025
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 12 investors for this company. to use credits for reveals, or explore the API.

About

Galecto is a clinical-stage biopharmaceutical company developing small-molecule and antibody therapeutics targeting galectin proteins for the treatment of fibrosis, cancer, and hematologic disorders. Its pipeline includes programs for idiopathic pulmonary fibrosis and myeloproliferative neoplasms. In March 2026 the company announced a name change to Damora Therapeutics following its acquisition of Damora Therapeutics and a strategic pivot to mutant calreticulin-driven blood disorders.

Funding & Exit History

Data from Indexed.vcUpdated
Series CSeries CNov 2025
$285.0M

4 more events

  • IPO2020
  • Series D20204 investors
  • Series C20187 investors

Funding: Pre-Seed through Series C. Amounts, valuations, and investors where available.

Investors

Tech & App Stack

1 technology or app tracked

Every product and vendor across these categories, with where each signal came from.

  • Cloud/Infrastructure ×1

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Companies in related industries

OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech
Private EquityTotal funding$647.0MFeb 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech
Private EquityTotal funding$2.3BFeb 2020
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech
Extension RoundTotal funding$1.2BNov 2021
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Galecto on Indexed.vc
<a href="https://indexed.vc/companies/galecto"><img src="https://indexed.vc/api/badge/company/galecto" alt="Galecto on Indexed.vc" width="260" height="76" /></a>